Last reviewed 2026-04-22 · How we verify

ITM + Usual Care

First Affiliated Hospital, Sun Yat-Sen University · FDA-approved active Small molecule

ITM + Usual Care is a Small molecule drug developed by First Affiliated Hospital, Sun Yat-Sen University. It is currently FDA-approved for Type 2 diabetes mellitus management.

ITM (Intensive Insulin Management Therapy) combined with standard care optimizes blood glucose control through structured insulin dosing protocols.

ITM (Intensive Insulin Management Therapy) combined with standard care optimizes blood glucose control through structured insulin dosing protocols. Used for Type 2 diabetes mellitus management.

At a glance

Generic name	ITM + Usual Care
Sponsor	First Affiliated Hospital, Sun Yat-Sen University
Modality	Small molecule
Therapeutic area	Endocrinology/Diabetes
Phase	FDA-approved

Mechanism of action

ITM represents a comprehensive insulin management approach that typically involves frequent glucose monitoring, individualized insulin titration, and patient education integrated with usual care practices. This combination aims to achieve tighter glycemic control and reduce diabetes-related complications compared to standard care alone.

Approved indications

Type 2 diabetes mellitus management

Common side effects

Hypoglycemia
Weight gain
Injection site reactions

Key clinical trials

Intrathecal Morphine for Postoperative Analgesia in Major Laparoscopic Abdominal Surgery, a IMPACT-Scope Trial (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ITM + Usual Care CI brief — competitive landscape report
ITM + Usual Care updates RSS · CI watch RSS
First Affiliated Hospital, Sun Yat-Sen University portfolio CI

Frequently asked questions about ITM + Usual Care

What is ITM + Usual Care?

ITM + Usual Care is a Small molecule drug developed by First Affiliated Hospital, Sun Yat-Sen University, indicated for Type 2 diabetes mellitus management.

How does ITM + Usual Care work?

ITM (Intensive Insulin Management Therapy) combined with standard care optimizes blood glucose control through structured insulin dosing protocols.

What is ITM + Usual Care used for?

ITM + Usual Care is indicated for Type 2 diabetes mellitus management.

Who makes ITM + Usual Care?

ITM + Usual Care is developed and marketed by First Affiliated Hospital, Sun Yat-Sen University (see full First Affiliated Hospital, Sun Yat-Sen University pipeline at /company/first-affiliated-hospital-sun-yat-sen-university).

What development phase is ITM + Usual Care in?

ITM + Usual Care is FDA-approved (marketed).

What are the side effects of ITM + Usual Care?

Common side effects of ITM + Usual Care include Hypoglycemia, Weight gain, Injection site reactions.

Manufacturer: First Affiliated Hospital, Sun Yat-Sen University — full pipeline
Therapeutic area: All drugs in Endocrinology/Diabetes
Indication: Drugs for Type 2 diabetes mellitus management

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing